Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by TheRock07on May 12, 2016 8:28am
179 Views
Post# 24865175

RE:RE:Q1 Results

RE:RE:Q1 ResultsCOGS ( Cost of good sold ) is declining rapidly.

COGS for the three months ended March 31, 2016, was $3.1-million, compared with $2.4-million for the three months ended March 31, 2015.

Product sales doubled from $3.7 million in Q1/15 to $7.3 million in Q1/16.

That is, a near doubling of sales was generated by only a 29 % increase in COGS.

This reflects economies of scale ( cost inverse to volume ) to which I alluded to in late 2015.

As a consequence, we are seeing gross margins increasing to 57 % in Q1/16 compared with 35 % in Q1/15


With product sales estimated to be about 35-40 % higher in Q2, we should see unit costs continueing to decline and gross margins edging higher..
Bullboard Posts